Genmab A/S (OTCMKTS:GNMSF) Short Interest Update

Genmab A/S (OTCMKTS:GNMSF) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 73,000 shares, an increase of 30.1% from the March 31st total of 56,100 shares. Based on an average daily trading volume, of 16,800 shares, the short-interest ratio is currently 4.3 days. Approximately 0.1% of the company’s stock are sold short.

Genmab A/S Price Performance

Shares of OTCMKTS GNMSF opened at $220.09 on Friday. The company has a 50-day moving average price of $201.56 and a 200-day moving average price of $208.42. Genmab A/S has a 1 year low of $170.00 and a 1 year high of $305.09. The stock has a market capitalization of $14.54 billion, a P/E ratio of 12.56 and a beta of 1.10.

Genmab A/S (OTCMKTS:GNMSF) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $5.70 EPS for the quarter, beating the consensus estimate of $0.46 by $5.24. Genmab A/S had a return on equity of 19.75% and a net margin of 36.30%.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.